title: Effect of nonanticoagulant heparin (Astenose) on restenosis after balloon angioplasty in the atherosclerotic rabbit.
abstract: OBJECTIVE
  To determine whether intravenous administration of Astenose, a high-molecular-weight nonanticoagulant heparin, can reduce restenosis following balloon angioplasty in a rabbit model.
  
  
  METHODS
  Focal atherosclerosis was induced in 54 rabbits (89 vessel), and angioplasty was performed after animals were randomized into five groups. Group 1 vessels (control) were treated with lactated Ringer solution for 28 days (n = 19); group 2, Astenose at 0.10 mg/kg per hour for 28 days (n = 16); group 3, Astenose at 0.33 mg/kg per hour for 28 days (n = 16); group 4, Astenose at 0.60 mg/kg per hour for 28 days (n = 17); and group 5, Astenose at 0.33 mg/kg per hour for 14 days (n = 21). Arteriograms were obtained to measure minimal luminal diameters before, immediately after, and 28 days after angioplasty, and the rabbits were killed for histologic analysis.
  
  
  RESULTS
  Angiographically demonstrated restenosis was significantly reduced in groups 3 (18.9% +/- 3.7, P = .04) and 4 (20.2% +/- 3.1, P = .04) compared with the control group (32.4% +/- 4.8). Group 5 showed a nonsignificant trend toward reduced restenosis (23.1% +/- 2.9, P = .09), and group 2 showed restenosis similar to that in group 1 (31.0% +/- 2.5, P = .80). However, quantitative histopathologic analysis detected no differences among the groups in absolute plaque area. Medial area was significantly smaller in groups 2 and 5 (P < or = .002) than in group 1, and there was a nonsignificant trend toward reduced medial area in groups 3 and 4 (P = .12).
  
  
  CONCLUSIONS
  Long-term intravenous Astenose therapy resulted in a modest but statistically significant reduction in angiographically demonstrated restenosis after angioplasty in this atherosclerotic rabbit model.
authors.affiliation: Department of Radiology, Hospital of the University of Pennsylvania, University of Pennsylvania, School of Medicine, Philadelphia 19104, USA.
authors.forename: I D
authors.initials: ID
authors.lastname: Timms
authors.forename: J E
authors.initials: JE
authors.lastname: Tomaszewski
authors.forename: R D
authors.initials: RD
authors.lastname: Shlansky-Goldberg
mesh_terms: D000792:Angiography; D000800:Angioplasty, Balloon; D000818:Animals; D001161:Arteriosclerosis / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D004547:Elastic Tissue / Q000473:pathology; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000473:pathology; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D015918:Infusion Pumps, Implantable; D007262:Infusions, Intravenous; D007552:Isotonic Solutions; D008297:Male; D010314:Partial Thromboplastin Time; D011446:Prospective Studies; D011817:Rabbits; D012008:Recurrence; D000077325:Ringer's Lactate; D017539:Tunica Intima / Q000473:pathology; D017540:Tunica Media / Q000473:pathology
chemical_list: D007552:Isotonic Solutions; D000077325:Ringer's Lactate; C092386:astenose; D006493:Heparin